Administered intravenously, the monoclonal antibody MK-2060 has a "novel approach" to anticoagulation by blocking the ...

Improving Global Outcomes (KDIGO) counsel that immunosuppressive therapy for lupus nephritis should typically be continued for at least 3 to 5 years after complete renal remission, with treatment ...

In contrast, when using the traditional race-adjusted creatinine-based equation (eGFRcr-ASR), the HR was 2.8 (95% CI, 1.6–4.9 ...

Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering ...

3 4 Next, the investigators categorised the patient cohort into ... While this definition is commonly used in nephrology clinical trials, it differs from the KDIGO (Kidney Disease: Improving Global ...

KDIGO 1 (risk for renal injury), in the presence of an increase in serum creatinine (SCr) of 0.3 mg/dL in 48 hours or an increase of 1.5 times or 1.9 times the baseline value in seven days; KDIGO 2 ...

Postoperative renal insufficiency was determined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria (Stage 1, Stage 2, and Stage 3) 9 9 Parlar H, Şaşkın H. Are pre and ...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including ...

If blood pressure is too high, the 3 readings may be repeated once within the Screening period if clinically appropriate as per the Investigator. * Clinical suspicion of IgAN with rapidly progressive ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.